Axovant: Up on positive data from gene therapy trial for Parkinson's disease

Sio Gene Therapies

13/01/2020 13:58

** Shares of gene therapy developer  AXGT.O  up 9.6% at $5.5
premarket - set for their best day in nearly 2 months
    ** Co says its gene therapy, AXO-Lenti-PD, to treat
Parkinson's disease showed positive data over a 12-month trial
period  urn:newsml:reuters.com:*:nGNXbJSHd5
    ** Therapy was well tolerated with no serious adverse
affects - AXGT 
    ** Co expects to report mid-stage trial data testing
AXO-Lenti-PD by end of this year
    ** Up to Friday's close, stock had fallen ~50% in the last
12 months

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6749 0647;))